Nykode Therapeutics Asa · OSL:NYKD
Nykode Therapeutics Asa — Q3 2024 Earnings Presentation
23 slides from Nykode Therapeutics Asa's earnings presentation, Nov 27, 2024
Slide 1: Q3 2024 Results Presentation
Q3 2024 Results Presentation November 27, 2024
Slide 2: Forward-looking statement
Forward-looking statement This announcement and any materials distributed in connection with this presentation may contain certain forward- looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumpt
Slide 3: Today's presenters from Nykode
Today’s presenters from Nykode MICHAEL ENGSIG AGNETE FREDRIKSEN HARALD GURVIN MARTIN NICKLASSON Chief Executive Officer Chief Scientific Officer & Chief Financial Officer Chairman of the Board of Business Development Directors Nykode Therapeutics | Q3 '24 webcast | Non-confidential 3
Slide 4: Strategic refocus to realign financial resources and cash runway with organizational priorities
Strategic refocus to realign financial resources and cash runway with organizational priorities • The strategic refocus aims to reach an annualized cost base of approximately USD 20m, extending the cash runway into 2030. • Nykode will transition into a leaner, research and technology driven organiza
Slide 5: Existing oncology assets
Existing oncology assets VB10.16 VB10.NEO Determine next steps for further clinical data generation Determine next steps for further clinical data generation Explore potential targeted, cost-effective clinical activities Conclude negotiations with Genentech1 Continue exploring partnership opor
Slide 6: Catalysts for growth
Catalysts for growth ONCOLOGY RESEARCH IMMUNE-TOLERANCE Cancer vaccine field is focusing on adjuvant treatment with The immune-tolerance field is gaining traction and multiple important ph2/3 trials ongoing. partnership interest from major players. Build on Nykode competencies in AI, antigen selec
Slide 7: VB10.NEO Individualized cancer immunotherapy
VB10.NEO Individualized cancer immunotherapy Nykode Therapeutics | Q3 '24 webcast | Non-confidential 7
Slide 8: VB10.NEO: Nykode's individualized cancer vaccine
VB10.NEO: Nykode’s individualized cancer vaccine Nykode regained control of VB10.NEO and its IP following termination of collaboration agreement by Genentech VB10.NEO has been tested in 2 clinical trials, N-01 and N-02, in recurrent/ metastatic patients across >10 solid tumors types. N-02, des
Slide 9: Preliminary data from VB-N-02 confirms VB10.NEO's potential
Preliminary data from VB- N-02 confirms VB10.NEO’s potential Preliminary immunogenicity data from the VB-N-02 trial confirms earlier observations from the N-01 trial1: 100 85 85 88 VB-N-01 58 45 VB-N-02 % immunogenic NeoAG % of patients with at % of patients with at least 1 least 1 de novo response
Slide 10: mRNA oncology vaccine
mRNA oncology vaccine Nykode Therapeutics | Q3 '24 webcast | Non-confidential 10
Slide 11: Nykode's APC targeting technology can leverage mRNA vaccines and presents opportunity for platform expansion
Nykode’s APC targeting technology can leverage mRNA vaccines and presents opportunity for platform expansion Targeted delivery via APCs using Nykode’s technology has been shown to induce broader and stronger CD8+ immune responses vs. existing ‘antigen-alone’ approaches. Preclinical studies have demo
Slide 12: Superior dose-response kinetics of Nykode's neoantigen vaccine compared to a control
Superior dose-response kinetics of Nykode’s neoantigen vaccine compared to a control neoantigen vaccine Nykode’s neoantigen vaccine elicits stronger T cell responses with a different dose-response for individual neoantigens Total Response Dose response to individual neoantigens (prime + boost) Nykod
Slide 13: Autoimmunity platform update
Autoimmunity platform update Nykode Therapeutics | Q3 '24 webcast | Non-confidential 13
Slide 14: Recent autoimmunity updates further substantiate the potential of Nykode's APC-targeted platform
Recent autoimmunity updates further substantiate the potential of Nykode’s APC-targeted platform • New data highlight the versatility and effectiveness of Nykode’s APC-targeting technology within the broad field of immune tolerance • Efficacy in therapeutic setting clearly differentiating from non-t
Slide 15: Induction of antigen specific tolerance by targeting epitopes to tolerogenic APCs
Induction of antigen specific tolerance can be achieved by targeting disease causing epitopes to tolerogenic APCs MECHANISM OF ACTION – TOLERANCE INDUCTION (INVERSE VACCINATION) Cells transfected with Effector DNA plasmid B cell vaccine Tol CD4+ Treg APC CD4+ Treg Tol APC Effector Effector T cell T
Slide 16: APC targeting is required for effective early therapy of EAE disease
APC targeting is required for effective early therapy of EAE disease EAE MODEL – EARLY THERAPEUTIC DELIVERY 30 µg 10 µg 3 µg Tol. Targeted APC 4 Non-targeted 4 5 PBS 4 EAE score (0-8) EAE score (0-8) EAE score (0-8) 3 3 3 2 2 2 1 1 1 0 0 0 MOG MOG * 10 12 14 16 20 22 24 26 28 6 8 * 10 12 14 16 20 22
Slide 17: Early therapeutic treatment alleviates disease progression in relapsing-remitting EAE
Early therapeutic treatment with Nykode vaccine alleviates disease progression in relapsing-remitting EAE RELAPSING-REMITTING EAE MODEL – EARLY THERAPEUTIC DELIVERY PLP (139-151) recall assay using splenocytes, day 35 3 Proteolipid protein Targeted PLP(139-151) PBS ✱✱ IL-17 100 ✱✱ EAE score (0-8) 15
Slide 18: Q3 2024 Financial Results
Q3 2024 Financial Results
Slide 19: Income Statement
Income Statement Revenue from contracts with customers Amounts in USD ‘000 Q3 2024 Q3 2023 YTD 2024 YTD 2023 • R&D activities under Genentech and Regeneron Revenue from contracts with customers 536 2,760 1,907 10,886 agreements Other income 129 51 358 332 • $0.5m (Q3 2024) and $1.7m (YTD 2024) under
Slide 20: Balance Sheet
Balance Sheet Cash and cash equivalents Amounts in USD ‘000 30/09/2024 31/12/2023 • Strong cash position of $124.6m at September 30, ASSETS 2024 Non-current assets Other non-current receivables Property, plant and equipment 3,875 4,413 Right-of-use assets 4,844 6,104 • Mainly reflects the NOK 325 mi
Slide 21: Balance Sheet - contd.
Balance Sheet - contd. Amounts in USD ’000 30/09/2024 31/12/2023 Equity EQUITY AND LIABILITIES • Total equity of $142.6m as per September 30, 2024 Equity Share capital 367 367 • Equity ratio of 85% Share premium 128,986 128,986 Other capital reserves 18,344 15,395 Other components of equity (3,053)
Slide 22: Summary and conclusions
Summary and conclusions • Maintained strong cash position of USD 124.6m as of September 30, 2024. • Strategic review aimed at realigning financial resources and cash runway with organizational priorities, targeting an annualized cost base of approximately USD 20m, extending cash runway into 2030. •
Slide 23: Unlocking the future of medicine
UNLOCKING THE FUTURE OF MEDICINE Contact: Alexandra Deschner Head of Investor Relations IR@nykode.com Nykode Therapeutics | Q3 '24 webcast | Non-confidential
Nykode Therapeutics As — Q3 2024 Earnings Presentation on 6ix